在患有严重心力衰竭的患者中使用芬瑞:FINEARTS-HF试验
Riccardo M Inciardi1,2, Henri Lu2,3, Brian L Claggett2
1ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
European journal of heart failure
|November 4, 2025
概括
严重心力衰竭 (HF) 患者面临更高的心血管风险. 药物finerenone有效地减少了这些患者的HF事件和心血管死亡,在HF严重程度上显示出类似的安全性和有效性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的心力衰竭 (HF) 越来越多地被识别为左心室喷射小部分 (LVEF) 的全谱.
- 在历史上,严重高血压炎患者的LVEF有所减少,但现在包括那些LVEF保持或轻微减少的患者.
- 识别严重的HF对于风险分层和治疗优化至关重要.
研究的目的:
- 在FINEARTS-HF试验中评估严重HF的患病率.
- 评估患有严重心血管炎的患者心血管 (CV) 结局风险.
- 为了确定患有严重HF的患者对芬瑞龙的治疗反应.
主要方法:
- 根据适应的多参数ESC-HFA标准,患者被归类为患有严重的HF.
- 标准包括NYHA类III/IV,最近HF住院和健康状况受损 (KCCTSS<75).
- 对HF事件和心血管死亡的费内伦治疗效应被分析为严重的HF状态.
主要成果:
- 14.8%的患者符合严重HF的标准.
- 严重的HF患者年龄较大,患病并发症较多,NT-proBNP水平较高.
- 费内伦降低了主要终点 (HF事件和心血管死亡),无论HF严重程度如何,在严重的HF患者中绝对风险降低更大.
- 治疗中止和不良事件在严重的HF组中是相似的.
结论:
- 严重的HF,无论LVEF,都与心血管事件风险增加有关.
- 芬瑞诺在患有严重HF的患者中显示出安全性和有效性,包括那些轻微减少或保持LVEF的患者.
相关概念视频
01:30Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
01:22Heart Failure VI: Adjunct Therapies
245
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
245
01:22Heart Failure Drugs: Diuretics
788
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
788
01:22Heart Failure Drugs: β-Blockers
755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
01:29Heart Failure II: Pathophysiology
699
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
699